Edwards Lifesciences (NYSE:EW) Reaches New 52-Week High – What’s Next?

Edwards Lifesciences Corporation (NYSE:EW) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $89.60 and last traded at $88.7180, with a volume of 1681237 shares trading hands. The stock had previously closed at $86.28.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Robert W. Baird raised their target price on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. Mizuho set a $95.00 price target on Edwards Lifesciences and gave the company an “outperform” rating in a research note on Monday, April 13th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday, April 20th. TD Cowen reaffirmed a “buy” rating and issued a $104.00 price target (up from $97.00) on shares of Edwards Lifesciences in a research note on Tuesday, June 2nd. Finally, Evercore reaffirmed an “outperform” rating and issued a $93.00 price target on shares of Edwards Lifesciences in a research note on Friday, April 24th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $95.96.

Edwards Lifesciences Price Performance

The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The firm has a market cap of $51.53 billion, a P/E ratio of 47.59, a PEG ratio of 2.13 and a beta of 0.87. The company has a fifty day moving average price of $82.88 and a two-hundred day moving average price of $83.10.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. During the same quarter in the previous year, the business posted $0.64 EPS. Edwards Lifesciences’s revenue for the quarter was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 620 shares of the stock in a transaction on Monday, May 18th. The shares were sold at an average price of $81.14, for a total transaction of $50,306.80. Following the completion of the sale, the vice president owned 40,411 shares of the company’s stock, valued at $3,278,948.54. This represents a 1.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares of the company’s stock, valued at $8,521,962.62. This represents a 19.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 81,038 shares of company stock worth $6,683,255 over the last three months. 0.31% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Edwards Lifesciences by 0.5% during the third quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock worth $5,472,147,000 after buying an additional 365,581 shares in the last quarter. State Street Corp grew its holdings in shares of Edwards Lifesciences by 1.5% during the fourth quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock worth $2,215,777,000 after buying an additional 371,892 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Edwards Lifesciences by 4.8% during the fourth quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock worth $1,857,934,000 after buying an additional 989,533 shares in the last quarter. Norges Bank bought a new position in shares of Edwards Lifesciences during the fourth quarter worth about $803,686,000. Finally, Morgan Stanley increased its stake in Edwards Lifesciences by 12.4% in the 4th quarter. Morgan Stanley now owns 7,314,292 shares of the medical research company’s stock valued at $623,544,000 after buying an additional 804,942 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.